248 related articles for article (PubMed ID: 22382151)
1. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.
Siberry GK; Williams PL; Mendez H; Seage GR; Jacobson DL; Hazra R; Rich KC; Griner R; Tassiopoulos K; Kacanek D; Mofenson LM; Miller T; DiMeglio LA; Watts DH;
AIDS; 2012 Jun; 26(9):1151-9. PubMed ID: 22382151
[TBL] [Abstract][Full Text] [Related]
2. Maternal Tenofovir Disoproxil Fumarate Use in Pregnancy and Growth Outcomes among HIV-Exposed Uninfected Infants in Kenya.
Pintye J; Langat A; Singa B; Kinuthia J; Odeny B; Katana A; Nganga L; John-Stewart G; McGrath CJ
Infect Dis Obstet Gynecol; 2015; 2015():276851. PubMed ID: 26823647
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir exposure in utero and linear growth in HIV-exposed, uninfected infants.
M le Roux S; Jao J; Brittain K; Phillips TK; Olatunbosun S; Ronan A; Zerbe A; Abrams EJ; Myer L
AIDS; 2017 Jan; 31(1):97-104. PubMed ID: 27898591
[TBL] [Abstract][Full Text] [Related]
4. Does maternal use of tenofovir during pregnancy affect growth of HIV-exposed uninfected infants?
Kuhn L; Bulterys M
AIDS; 2012 Jun; 26(9):1167-9. PubMed ID: 22592070
[No Abstract] [Full Text] [Related]
5. Safety of tenofovir during pregnancy: early growth outcomes and hematologic side effects in HIV-exposed uninfected infants.
Seidel V; Weizsäcker K; Henrich W; Rancourt RC; Bührer C; Krüger R; Feiterna-Sperling C
Eur J Pediatr; 2020 Jan; 179(1):99-109. PubMed ID: 31659467
[TBL] [Abstract][Full Text] [Related]
6. Lower birth weight-for-age and length-for-age z-scores in infants with in-utero HIV and ART exposure: a prospective study in Cape Town, South Africa.
Nyemba DC; Kalk E; Madlala HP; Malaba TR; Slogrove AL; Davies MA; Boulle A; Myer L; Powis KM
BMC Pregnancy Childbirth; 2021 May; 21(1):354. PubMed ID: 33947351
[TBL] [Abstract][Full Text] [Related]
7. Growth trajectories of breastfed HIV-exposed uninfected and HIV-unexposed children under conditions of universal maternal antiretroviral therapy: a prospective study.
le Roux SM; Abrams EJ; Donald KA; Brittain K; Phillips TK; Nguyen KK; Zerbe A; Kroon M; Myer L
Lancet Child Adolesc Health; 2019 Apr; 3(4):234-244. PubMed ID: 30773459
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
[TBL] [Abstract][Full Text] [Related]
9. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
Gibb DM; Kizito H; Russell EC; Chidziva E; Zalwango E; Nalumenya R; Spyer M; Tumukunde D; Nathoo K; Munderi P; Kyomugisha H; Hakim J; Grosskurth H; Gilks CF; Walker AS; Musoke P;
PLoS Med; 2012; 9(5):e1001217. PubMed ID: 22615543
[TBL] [Abstract][Full Text] [Related]
10. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.
Ransom CE; Huo Y; Patel K; Scott GB; Watts HD; Williams P; Siberry GK; Livingston EG;
J Acquir Immune Defic Syndr; 2013 Dec; 64(4):374-81. PubMed ID: 24169122
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
[TBL] [Abstract][Full Text] [Related]
12. Higher prevalence of stunting and poor growth outcomes in HIV-exposed uninfected than HIV-unexposed infants in Kenya.
Neary J; Langat A; Singa B; Kinuthia J; Itindi J; Nyaboe E; Ng'anga' LW; Katana A; John-Stewart GC; McGrath CJ
AIDS; 2022 Mar; 36(4):605-610. PubMed ID: 34750290
[TBL] [Abstract][Full Text] [Related]
13. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review.
Wang L; Kourtis AP; Ellington S; Legardy-Williams J; Bulterys M
Clin Infect Dis; 2013 Dec; 57(12):1773-81. PubMed ID: 24046310
[TBL] [Abstract][Full Text] [Related]
14. Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis.
Nachega JB; Uthman OA; Mofenson LM; Anderson JR; Kanters S; Renaud F; Ford N; Essajee S; Doherty MC; Mills EJ
J Acquir Immune Defic Syndr; 2017 Sep; 76(1):1-12. PubMed ID: 28291053
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.
Mofenson LM; Baggaley RC; Mameletzis I
AIDS; 2017 Jan; 31(2):213-232. PubMed ID: 27831952
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.
Mirochnick M; Taha T; Kreitchmann R; Nielsen-Saines K; Kumwenda N; Joao E; Pinto J; Santos B; Parsons T; Kearney B; Emel L; Herron C; Richardson P; Hudelson SE; Eshleman SH; George K; Fowler MG; Sato P; Mofenson L;
J Acquir Immune Defic Syndr; 2014 Jan; 65(1):33-41. PubMed ID: 23979002
[TBL] [Abstract][Full Text] [Related]
17. Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial.
Stranix-Chibanda L; Tierney C; Pinilla M; George K; Aizire J; Chipoka G; Mallewa M; Naidoo M; Nematadzira T; Kusakara B; Violari A; Mbengeranwa T; Njau B; Fairlie L; Theron G; Mubiana-Mbewe M; Khadse S; Browning R; Fowler MG; Siberry GK;
PLoS One; 2021; 16(8):e0255250. PubMed ID: 34415933
[TBL] [Abstract][Full Text] [Related]
18. In Utero Exposure to Antiretroviral Drugs: Effect on Birth Weight and Growth Among HIV-exposed Uninfected Children in Brazil.
Hofer CB; Keiser O; Zwahlen M; Lustosa CS; Frota AC; de Oliveira RH; Abreu TF; Carvalho AW; Araujo LE; Egger M
Pediatr Infect Dis J; 2016 Jan; 35(1):71-7. PubMed ID: 26741583
[TBL] [Abstract][Full Text] [Related]
19. Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
Chetty T; Thorne C; Coutsoudis A
PLoS One; 2018; 13(2):e0192805. PubMed ID: 29470508
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
